Stokes Pharmacy, a leading veterinary compounding pharmacy,
announces an exclusive partnership with the Bova Group to offer a
U.S.-made oral treatment for FIP, or Feline Infectious Peritonitis.
Compounded GS-441524 will be available June
1 by veterinary prescription for individual patients and for
veterinary office use in permitted states. For more information, go
to stokespharmacy.com/fip.
MOUNT
LAUREL, N.J., May 21, 2024
/PRNewswire-PRWeb/ -- Stokes Pharmacy, a leading veterinary
compounding pharmacy, announces an exclusive partnership with
the Bova Group to offer a U.S.-made oral treatment for FIP, or
Feline Infectious Peritonitis. Veterinarians will now be able to
manage this once-fatal virus with Stokes Pharmacy's compounded
preparation, which is supported by Bova's unique drug formula that
has been utilized in clinical research studies across the globe and
is currently in use by Bova Aus and
Bova UK, with exports to other countries with import permissions in
place.
Stokes Pharmacy, a leading veterinary
compounding pharmacy, announces an exclusive partnership with the
Bova Group to offer a U.S.-made oral treatment for FIP, or Feline
Infectious Peritonitis.
Previous attempts to treat FIP involved medications like
prednisolone, interferon, and polyprenyl immunostimulant. These
treatments were largely unsuccessful, often resulting in
euthanasia. GS-441524 tablets are now available in a quad-scored,
50 mg tuna-flavored tablet with dosages that address FIP diagnoses,
including:
- With effusions but without any ocular or neurological
involvement (wet FIP)
- No effusion and without ocular or neurological signs (dry
FIP)
- With ocular signs (no neurological involvement)
- With neurological signs
Stokes' president, Michael Tursi,
states, "Made possible by our Bova partnership, Stokes Pharmacy
will compound and sell the only oral formula identical to the Bova
formula used in clinical studies across the globe. Our tablets were
tested by Bova to meet their exact specifications. We are thrilled
to bring this long-awaited treatment to the United States and put FIP treatment back
in the hands of the veterinarians."
With no legal access to oral FIP treatment available in the
U.S., veterinarians and pet owners have previously relied on
options sourced outside a pharmacy or FDA-registered manufacturer.
Bova, recognizing this gap in veterinary medicine, vetted industry
leaders to find the right partner to bring their formula to the
U.S. market. Stokes' and Bova's shared commitment to raising the
standard of care in animal health through high-quality medications
is the foundation of this exclusive partnership.
Bova's Managing Director, Nick
Bova, states, "The introduction of FIP products to
Australia and subsequently to the
UK has led us on a transformative path. Collaborating with Feline
Specialists around the world has propelled the progression of
knowledge and comprehension of FIP. At Bova, we have been fortunate
enough to support multiple clinical trials around the world on our
unique formulation. This has helped give veterinarians confidence
in using our formula and bringing the treatment of this fatal
disease back under their control. There are so many black-market
options available out there and their quality is so varied. We
wanted a partner who took quality and science as seriously as we do
at Bova. Stokes Pharmacy is an impressive organization that
prioritizes quality and science. Now, together, we can finally help
save cats' lives across the USA
who are impacted by this terrible disease."
FDA's Center for Veterinary Medicine (CVM) has notified
veterinarians that compounded GS-441524 falls under Guidance for
Industry #256 and is allowed to be compounded and legally
prescribed. Stokes has nominated GS to be included on the animal
drug bulk substances list regarding GFI #256 office use and it is
now on the GFI under review list. This means that GS-441524 50 mg
tablets can be sold to hospitals for office use in all states
except Arkansas, Maine, Massachusetts, New
Mexico, New York,
Oregon, Rhode Island, and West Virginia. Veterinarians who work in a
state that does not allow compounded medications for office use can
prescribe the drug in a patient's name.
Compounded GS-441524 will be available June 1 by veterinary prescription for individual
patients and for veterinary office use in permitted states. For
more information, go to stokespharmacy.com/fip.
About Stokes Healthcare:
Stokes Pharmacy, a division of Stokes Healthcare, has been
formulating custom prescription medications for both humans and
animals since 1975. It has grown from a small hometown operation to
a nationally respected compounding pharmacy. In 2018, Stokes
Healthcare developed Epicur Pharma, an FDA-Registered 503B outsourcing facility, to serve the evolving
needs of veterinary practices as regulations and laws changed,
including GFI 256 and USP guidelines. Epicur manufactures
standardized and tested bulk medications for hospital use following
current Good Manufacturing Processes (cGMP). Each brand
demonstrates Stokes' longstanding commitment to quality and
improving patient outcomes with medication you trust. Learn more at
www.stokespharmacy.com
About Bova:
The Bova Group comprises Bova Aus
and Bova UK. Established in 1968 as a human pharmacy, Bova
transitioned to veterinary compounding in 2010 under Nick Bova's leadership. By 2016, it had become
the largest veterinary compounder in Australia, catering to numerous veterinarians
nationwide. Bova Aus has implemented
a robust quality assurance system for popular, high-risk, and
complex compounded products in collaboration with the Australian
Pesticides and Veterinary Medicines Authority (APVMA) to ensure
compliance with prevailing regulations, adhering to USP or BP
pharmacopoeia standards for quality control.
In 2017, Nick expanded operations to the UK with Bova UK, a
Specials Manufacturer focused on delivering high-quality Specials
Medications to the UK veterinary sector. Authorized by the
Veterinary Medicines Directorate, the facilities obtained a
Manufacturer 'Specials' Authorisation (ManSA) in 2017 for both
sterile and non-sterile medicines. The company upholds stringent
quality standards compliant with current Good Manufacturing
Practices (cGMP) and Good Laboratory Practices (GLP) as outlined by
the European Medicine Standards. For further information, please
visit www.bova.vet.
Media Contact
Michael Tursi, Stokes Healthcare,
1 856-208-7811, mtursi@stokeshealthcare.com,
https://www.stokespharmacy.com/
View original content to download
multimedia:https://www.prweb.com/releases/us-made-compounded-oral-treatment-for-feline-infectious-peritonitis-now-available-302151712.html
SOURCE Stokes Healthcare